Tag: Interstitial Lung Disease

April 8, 2019

Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse

Bellerophon Therapeuetics (NASDAQ:BLPH) has announced it and the US Food and Drug Administration (FDA) have agreed on a regulatory approval...
January 28, 2019

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial...
October 9, 2018

Bellerophon Updates Ongoing Phase 2b Trial

Bellerophon Therapeutics announced the completion of enrolment for its iNO-PF trial and said it expects top-line results in January 2019.
October 9, 2018

Bellerophon Provides Update on INOpulse Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled...